NCT02279602 - Rollover Protocol for Subjects Who Have Responded on Study 4218s - A Phase 2 Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions

Neuroendocrine Tumors

Interventions

DRUG

fosbretabulin

fosbretabullin, 60 mg/m2 weekly for up to 1 year

Trial Locations (5)

Montefiore, The Bronx

Duke University Medical Center, Durham

Markey Cancer Center, Clinical Research Office, Lexington

Froedtert Hospital, Medicial College of Wisconsin, Milwaukee

Stanford University School of Medicine, Stanford